The active core in a triazole peptide dual-site antagonist of HIV-1 gp120

Muddegowda Umashankara, Karyn McFadden, Isaac Zentner, Arne Schön, Srivats Rajagopal, Ferit Tuzer, Syna A. Kuriakose, Mark Contarino, Judith Lalonde, Ernesto I Freire, Irwin Chaiken

Research output: Contribution to journalArticle

Abstract

In an effort to identify broadly active inhibitors of HIV-1 entry into host cells, we previously reported a family of dodecamer triazole-peptide conjugates with nanomolar affinity for the viral surface protein gp120. This peptide class exhibits potent antiviral activity and the capacity to simultaneously inhibit interaction of the viral envelope protein with both CD4 and co-receptor. In this investigation, we minimized the structural complexity of the lead triazole inhibitor HNG-156 (peptide 1) to explore the limits of the pharmacophore that enables dual antagonism and to improve opportunities for peptidomimetic design. Truncations of both carboxy- and amino-terminal residues from the parent 12-residue peptide 1 were found to have minimal effects on both affinity and antiviral activity. In contrast, the central triazole(Pro)-Trp cluster at residues 6 and 7 with ferrocenyl-triazole(Pro) (Ftp) was found to be critical for bioactivity. Amino-terminal residues distal to the central triazole(Pro)-Trp sequence tolerated decreasing degrees of side chain variation upon approaching the central cluster. A peptide fragment containing residues 3-7 (Asn-Asn-Ile-Ftp-Trp) exhibited substantial direct binding affinity, antiviral potency, dual receptor site antagonism, and induction of gp120 structuring, all properties that define the functional signature of the parent compound 1. This active core contains a stereochemically specific hydrophobic triazole(Pro)-Trp cluster, with a short N-terminal peptide extension providing groups for potential main chain and side chain hydrogen bonding. The results of this work argue that the pharmacophore for dual antagonism is structurally limited, thereby enhancing the potential to develop minimized peptidomimetic HIV-1 entry inhibitors that simultaneously suppress binding of envelope protein to both of its host cell receptors. The results also argue that the target epitope on gp120 is relatively small, pointing to a localized allosteric inhibition site in the HIV-1 envelope that could be targeted for small-molecule inhibitor discovery. The core of the matter: Optimization of a previously identified 12-mer peptide HIV-1 entry inhibitor led to the discovery of the minimal amino acid sequence essential for dual antagonism and antiviral activity. A pentapeptide of sequence 3-7 in the parent compound (shown) exhibits the functional signature of the 12-mer. This suggests that the target epitope on gp120 for dual-site antagonism is structurally limited and amenable to targeting by small molecules or peptidomimetics.

Original languageEnglish (US)
Pages (from-to)1871-1879
Number of pages9
JournalChemMedChem
Volume5
Issue number11
DOIs
StatePublished - Nov 8 2010

Fingerprint

Triazoles
HIV-1
HIV Fusion Inhibitors
Peptidomimetics
Peptides
Antiviral Agents
Epitopes
Allosteric Site
Viral Envelope Proteins
CD4 Antigens
Peptide Fragments
Molecules
Viral Proteins
Hydrogen Bonding
Bioactivity
Amino Acid Sequence
Carrier Proteins
Hydrogen bonds
Membrane Proteins
Amino Acids

Keywords

  • click chemistry
  • entry inhibitors
  • HIV-1
  • peptide triazoles
  • surface plasmon resonance

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Umashankara, M., McFadden, K., Zentner, I., Schön, A., Rajagopal, S., Tuzer, F., ... Chaiken, I. (2010). The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem, 5(11), 1871-1879. https://doi.org/10.1002/cmdc.201000222

The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. / Umashankara, Muddegowda; McFadden, Karyn; Zentner, Isaac; Schön, Arne; Rajagopal, Srivats; Tuzer, Ferit; Kuriakose, Syna A.; Contarino, Mark; Lalonde, Judith; Freire, Ernesto I; Chaiken, Irwin.

In: ChemMedChem, Vol. 5, No. 11, 08.11.2010, p. 1871-1879.

Research output: Contribution to journalArticle

Umashankara, M, McFadden, K, Zentner, I, Schön, A, Rajagopal, S, Tuzer, F, Kuriakose, SA, Contarino, M, Lalonde, J, Freire, EI & Chaiken, I 2010, 'The active core in a triazole peptide dual-site antagonist of HIV-1 gp120', ChemMedChem, vol. 5, no. 11, pp. 1871-1879. https://doi.org/10.1002/cmdc.201000222
Umashankara M, McFadden K, Zentner I, Schön A, Rajagopal S, Tuzer F et al. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem. 2010 Nov 8;5(11):1871-1879. https://doi.org/10.1002/cmdc.201000222
Umashankara, Muddegowda ; McFadden, Karyn ; Zentner, Isaac ; Schön, Arne ; Rajagopal, Srivats ; Tuzer, Ferit ; Kuriakose, Syna A. ; Contarino, Mark ; Lalonde, Judith ; Freire, Ernesto I ; Chaiken, Irwin. / The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. In: ChemMedChem. 2010 ; Vol. 5, No. 11. pp. 1871-1879.
@article{a1a7632c138648b9b28b5492818c00f9,
title = "The active core in a triazole peptide dual-site antagonist of HIV-1 gp120",
abstract = "In an effort to identify broadly active inhibitors of HIV-1 entry into host cells, we previously reported a family of dodecamer triazole-peptide conjugates with nanomolar affinity for the viral surface protein gp120. This peptide class exhibits potent antiviral activity and the capacity to simultaneously inhibit interaction of the viral envelope protein with both CD4 and co-receptor. In this investigation, we minimized the structural complexity of the lead triazole inhibitor HNG-156 (peptide 1) to explore the limits of the pharmacophore that enables dual antagonism and to improve opportunities for peptidomimetic design. Truncations of both carboxy- and amino-terminal residues from the parent 12-residue peptide 1 were found to have minimal effects on both affinity and antiviral activity. In contrast, the central triazole(Pro)-Trp cluster at residues 6 and 7 with ferrocenyl-triazole(Pro) (Ftp) was found to be critical for bioactivity. Amino-terminal residues distal to the central triazole(Pro)-Trp sequence tolerated decreasing degrees of side chain variation upon approaching the central cluster. A peptide fragment containing residues 3-7 (Asn-Asn-Ile-Ftp-Trp) exhibited substantial direct binding affinity, antiviral potency, dual receptor site antagonism, and induction of gp120 structuring, all properties that define the functional signature of the parent compound 1. This active core contains a stereochemically specific hydrophobic triazole(Pro)-Trp cluster, with a short N-terminal peptide extension providing groups for potential main chain and side chain hydrogen bonding. The results of this work argue that the pharmacophore for dual antagonism is structurally limited, thereby enhancing the potential to develop minimized peptidomimetic HIV-1 entry inhibitors that simultaneously suppress binding of envelope protein to both of its host cell receptors. The results also argue that the target epitope on gp120 is relatively small, pointing to a localized allosteric inhibition site in the HIV-1 envelope that could be targeted for small-molecule inhibitor discovery. The core of the matter: Optimization of a previously identified 12-mer peptide HIV-1 entry inhibitor led to the discovery of the minimal amino acid sequence essential for dual antagonism and antiviral activity. A pentapeptide of sequence 3-7 in the parent compound (shown) exhibits the functional signature of the 12-mer. This suggests that the target epitope on gp120 for dual-site antagonism is structurally limited and amenable to targeting by small molecules or peptidomimetics.",
keywords = "click chemistry, entry inhibitors, HIV-1, peptide triazoles, surface plasmon resonance",
author = "Muddegowda Umashankara and Karyn McFadden and Isaac Zentner and Arne Sch{\"o}n and Srivats Rajagopal and Ferit Tuzer and Kuriakose, {Syna A.} and Mark Contarino and Judith Lalonde and Freire, {Ernesto I} and Irwin Chaiken",
year = "2010",
month = "11",
day = "8",
doi = "10.1002/cmdc.201000222",
language = "English (US)",
volume = "5",
pages = "1871--1879",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - The active core in a triazole peptide dual-site antagonist of HIV-1 gp120

AU - Umashankara, Muddegowda

AU - McFadden, Karyn

AU - Zentner, Isaac

AU - Schön, Arne

AU - Rajagopal, Srivats

AU - Tuzer, Ferit

AU - Kuriakose, Syna A.

AU - Contarino, Mark

AU - Lalonde, Judith

AU - Freire, Ernesto I

AU - Chaiken, Irwin

PY - 2010/11/8

Y1 - 2010/11/8

N2 - In an effort to identify broadly active inhibitors of HIV-1 entry into host cells, we previously reported a family of dodecamer triazole-peptide conjugates with nanomolar affinity for the viral surface protein gp120. This peptide class exhibits potent antiviral activity and the capacity to simultaneously inhibit interaction of the viral envelope protein with both CD4 and co-receptor. In this investigation, we minimized the structural complexity of the lead triazole inhibitor HNG-156 (peptide 1) to explore the limits of the pharmacophore that enables dual antagonism and to improve opportunities for peptidomimetic design. Truncations of both carboxy- and amino-terminal residues from the parent 12-residue peptide 1 were found to have minimal effects on both affinity and antiviral activity. In contrast, the central triazole(Pro)-Trp cluster at residues 6 and 7 with ferrocenyl-triazole(Pro) (Ftp) was found to be critical for bioactivity. Amino-terminal residues distal to the central triazole(Pro)-Trp sequence tolerated decreasing degrees of side chain variation upon approaching the central cluster. A peptide fragment containing residues 3-7 (Asn-Asn-Ile-Ftp-Trp) exhibited substantial direct binding affinity, antiviral potency, dual receptor site antagonism, and induction of gp120 structuring, all properties that define the functional signature of the parent compound 1. This active core contains a stereochemically specific hydrophobic triazole(Pro)-Trp cluster, with a short N-terminal peptide extension providing groups for potential main chain and side chain hydrogen bonding. The results of this work argue that the pharmacophore for dual antagonism is structurally limited, thereby enhancing the potential to develop minimized peptidomimetic HIV-1 entry inhibitors that simultaneously suppress binding of envelope protein to both of its host cell receptors. The results also argue that the target epitope on gp120 is relatively small, pointing to a localized allosteric inhibition site in the HIV-1 envelope that could be targeted for small-molecule inhibitor discovery. The core of the matter: Optimization of a previously identified 12-mer peptide HIV-1 entry inhibitor led to the discovery of the minimal amino acid sequence essential for dual antagonism and antiviral activity. A pentapeptide of sequence 3-7 in the parent compound (shown) exhibits the functional signature of the 12-mer. This suggests that the target epitope on gp120 for dual-site antagonism is structurally limited and amenable to targeting by small molecules or peptidomimetics.

AB - In an effort to identify broadly active inhibitors of HIV-1 entry into host cells, we previously reported a family of dodecamer triazole-peptide conjugates with nanomolar affinity for the viral surface protein gp120. This peptide class exhibits potent antiviral activity and the capacity to simultaneously inhibit interaction of the viral envelope protein with both CD4 and co-receptor. In this investigation, we minimized the structural complexity of the lead triazole inhibitor HNG-156 (peptide 1) to explore the limits of the pharmacophore that enables dual antagonism and to improve opportunities for peptidomimetic design. Truncations of both carboxy- and amino-terminal residues from the parent 12-residue peptide 1 were found to have minimal effects on both affinity and antiviral activity. In contrast, the central triazole(Pro)-Trp cluster at residues 6 and 7 with ferrocenyl-triazole(Pro) (Ftp) was found to be critical for bioactivity. Amino-terminal residues distal to the central triazole(Pro)-Trp sequence tolerated decreasing degrees of side chain variation upon approaching the central cluster. A peptide fragment containing residues 3-7 (Asn-Asn-Ile-Ftp-Trp) exhibited substantial direct binding affinity, antiviral potency, dual receptor site antagonism, and induction of gp120 structuring, all properties that define the functional signature of the parent compound 1. This active core contains a stereochemically specific hydrophobic triazole(Pro)-Trp cluster, with a short N-terminal peptide extension providing groups for potential main chain and side chain hydrogen bonding. The results of this work argue that the pharmacophore for dual antagonism is structurally limited, thereby enhancing the potential to develop minimized peptidomimetic HIV-1 entry inhibitors that simultaneously suppress binding of envelope protein to both of its host cell receptors. The results also argue that the target epitope on gp120 is relatively small, pointing to a localized allosteric inhibition site in the HIV-1 envelope that could be targeted for small-molecule inhibitor discovery. The core of the matter: Optimization of a previously identified 12-mer peptide HIV-1 entry inhibitor led to the discovery of the minimal amino acid sequence essential for dual antagonism and antiviral activity. A pentapeptide of sequence 3-7 in the parent compound (shown) exhibits the functional signature of the 12-mer. This suggests that the target epitope on gp120 for dual-site antagonism is structurally limited and amenable to targeting by small molecules or peptidomimetics.

KW - click chemistry

KW - entry inhibitors

KW - HIV-1

KW - peptide triazoles

KW - surface plasmon resonance

UR - http://www.scopus.com/inward/record.url?scp=78349264989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349264989&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201000222

DO - 10.1002/cmdc.201000222

M3 - Article

C2 - 20677318

AN - SCOPUS:78349264989

VL - 5

SP - 1871

EP - 1879

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 11

ER -